Camrelizumab and Apatinib Combination Therapy for Untreated Extensive-Stage Small Cell Lung Cancer

This is a treatment-focused, Phase II clinical trial for individuals with untreated extensive-stage small cell lung cancer (ES-SCLC). The main goal is to assess the safety and effectiveness of a combination therapy. This therapy includes Camrelizumab, an anti-programmed death-receptor 1 (PD-1) antibody, along with Apatinib, carboplatin, and etoposide. The importance of this study lies in its potential to find a new treatment approach for ES-SCLC, a condition with significant unmet medical needs. During the study, participants receive the combination therapy in 21-day cycles for four to six cycles, known as the induction phase. This is followed by a maintenance phase with Camrelizumab and Apatinib until progressive disease (PD) is observed. The progression of the disease is evaluated using specific criteria, known as Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The primary outcome measure is Progression-Free Survival (PFS), which is the time during and after treatment when the patient lives with the disease but it does not get worse.